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EDITORIALDoes Massive Antigen Burden Allow Hepatic Viruses to Induce
Regulatory T Cells and Their Tolerance and Persistence?egulatory T cells (Tregs), typically expressing CD25Rand the transcription factor forkhead box P3
(FoxP3)—which suppress effector T-cells via contact-
dependent mechanisms and immunosuppressive cytokines
such as interleukin 10 (IL-10) and transforming growth
factor b (TGFb)—play a critical role in the establishment of
chronic hepatitis infections in humans.1 Although primate
studies have contributed signiﬁcantly to our understanding
of innate and adaptive responses, and have shown that
Tregs are induced in both resolving and persistent viral
hepatitis infection, understanding the mechanisms by which
Tregs are themselves induced and then induce tolerance
in vivo has been hampered by the absence of a convenient
and authentic small-animal model of these infections.
An optimal model for dissecting the critical immuno-
suppressive processes most relevant during the acute and
chronic phases of hepatitis B and C viral (HBV and HCV)
infections would feature chronic infection by a highly pro-
ductive, primarily hepatotropic virus (ideally strains of
hepatitis C or B) in the absence of signiﬁcant systemic im-
munodeﬁciency. Ideally, such a model would also be
without germline defects in pattern-recognition receptor
systems, have some capability for humanization, and not
rely on potentially tolerogenic constitutive viral antigen
expression in the absence of infection. Such a model does
not yet exist. Until one is developed, we must glean an
improved understanding of the hierarchy of immunosup-
pressive pathways relevant in chronic hepatotropic viral
infections from creative but incomplete models.
Most liver-speciﬁc transgenic mouse models shed little
light on host–virus interaction because of their lack of sig-
niﬁcant immunogenicity. One of the ﬁrst transgenic models
to overcome this barrier involved mice with ﬂoxed HCV
structural core, E1, E2, and nonstructural NS2 constructs
induced to have hepatocyte-speciﬁc expression by adeno-
virally delivered Cre recombinase.2 In this model, a robust
cytotoxic CD8þ T-cell response against viral antigens
resulted in massive T-cell inﬁltration into the liver and an-
tigen clearance. When this model was recapitulated in
relatively CD8 T-cell–deﬁcient interferon regulatory factor-
1/ mice, transient hepatitis resulted, but the HCV-
expressing hepatocytes were not cleared despite the
persistence of virus-speciﬁc effector CD8þ T cells. These
early studies focused on the role of CD8þ T cells play in
hepatic inﬂammation, but they also suggested regulation of
cytotoxic T cells in vivo by mechanisms unknown at that
time.
Since that time, several mouse models of acute and
chronic hepatitis have provided strong evidence that Tregs
play a fundamental role in dampening the potentially dele-
terious impact of activated effector T cells. For instance, inCelluthe concanavalin A–induced mouse hepatitis model, which
is a frequently used model of human autoimmune and viral
hepatitis, the intrahepatic inﬂammatory cytokines produced
by effector T cells appear to induce the accumulation of
intrahepatic CD4þCD25þ regulatory T cells.3 These Tregs,
similar to human Tregs, express high levels of galectin-9,
which in this model induces apoptosis of CD4þCD25
effector T cells and attenuates liver inﬂammation. Due to the
stochastic nature of self-antigen expression in the conca-
navalin A model, the role of antigen recognition and the
immunoregulatory actions of speciﬁc viral proteins in the
generation of Tregs cannot be assessed.
However, vector-based models have demonstrated that
individual HCV proteins have a divergent impact on
endogenous T-cell responses in immunocompetent mice.
For example, when immunized with recombinant adenovi-
ruses encoding either HCV Core or NS3, wild-type C57BL/6
mice developed NS3-speciﬁc T cells exhibiting typical
effector cytokine and cytolytic responses, but generated
HCV core-speciﬁc T cells that were hypoproliferative, pre-
dominantly IL-10-producing, and enriched for CD4þfoxp3þ
Tregs.4 Although antigen-expression was not necessarily
hepatocyte speciﬁc, and no chronic infection occurred, this
model highlighted the potential role of HCV core protein
itself in establishing immunosuppressive conditions thought
likely to contribute to chronicity in humans.
Human liver/mouse chimeras offer the potential to
study the immunosuppressive impact of human hepato-
tropic viruses in the mouse system, but to date this po-
tential has not been fully realized for technical reasons.
The human liver-urokinase plasminogen activator/severe
combined immunodeﬁciency (uPA/SCID), nonobese dia-
betic/severe combined immunodeﬁciency (NOD/SCID),
and fumarylacetoacetate hydrolase-recombination acti-
vating gene/ gCnull (FAH-Rag/ gCnull) models can
support high-level human hepatocyte engraftment and can
support HCV5 or HBV6 replication but are immunodeﬁ-
cient. The AFC8-hu HSC/Hep model, in which Balb/C
Rag2/gCnull mice are cotransplanted with both human
hepatocyte progenitors and human CD34þ hematopoietic
stem cells (HSC), reconstituting the mouse with both hu-
man liver mass and a human immune system, can support
HCV infection.7 HCV infection in this model indeed pro-
duces liver inﬂammation, HCV-speciﬁc effector CD4þ and
CD8þ T-cells, stellate cell activation, and ﬁbrosis. However,
only half of the mice successfully support HCV infection,
human hepatic reconstitution in this model is modest
(15%), and there is no detectable viremia. Furthermore,
although T cells engraft well, the B-cell compartment does
not similarly reconstitute, resulting in a potentially biased
assessment of host immune responses.lar and Molecular Gastroenterology and Hepatology 2015;1:259–261
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involves human leukocyte antigen (HLA)-transgenic NOD/
SCID/IL2R/ mice reconstituted with CD34þ hematopoi-
etic stem cells. When exposed to HCV nonstructural antigens
via a nonproductive hepatotropic adenovirus, this model
generates strong HCV-speciﬁc HLA-A2-restricted T-cell re-
sponses that mediate partial but not complete adenoviral
clearance from the liver.8 The authors of this study postu-
lated that this incomplete clearance might be related to
incomplete reconstitution of the /gCnull NK and myeloid
compartments in the model, but did not report on regula-
tory T-cell induction as an alternative explanation. The lack
of viremia in this model also limits its authenticity. Thus,
human liver chimeric models, while promising, have not yet
explained the generation and function of hepatitis virus-
speciﬁc Tregs in mice in vivo.
Lymphocytic choriomeningitis virus (LCMV), while not a
hepacivirus or hepadnavirus, has features that make it
attractive for modeling human chronic viral hepatitis. First,
LCMV, while not liver speciﬁc, has strong hepatotropism.
Certain LCMV strains typically result in acute infections
whereas LCMV clone 13 results in a persistent infection.
Clone 13 infections induce early impairment of LCMV-
speciﬁc CD4þ T-cells with anergy, deviation of CD4þ
T-cells toward IL-10þ production, and inhibition of LCMV-
speciﬁc CD8þ T cells,9 similar to processes reported in the
transition from acute to chronic HCV infections in humans.
In the setting of uncontrolled viral replication induced by
macrophage depletion, LCMV-speciﬁc CD8þ T-cells can even
induce liver ﬁbrosis.10
In this issue of Cellular and Molecular Gastroenterology
and Hepatology, Lapierre and colleagues11 characterize the
dynamics of LCMV-speciﬁc CD4þ and CD8þ T-cell re-
sponses in the presence or absence of constitutive expres-
sion of a single subdominant nucleoprotein epitope (NP)
expressed using the transthyretin (TTR) promoter. When
exposed to two typically resolving strains of LCMV, TTR-NP
mice developed chronic infections. This appeared pre-
dominantly due to persistent intrahepatic virus and was
associated with increased serum alanine aminotransferase
(ALT) levels after 2 months and inﬁltration of effector CD4þ
and CD8þ T-cell numbers into the liver. However, relative
to T cells in wild-type mice, NP-speciﬁc CD4þ and CD8þ T
cells were reduced and CD4þ and CD8þ T-cells overex-
pressed the inhibitory costimulation marker programmed
death-1 (PD-1) and had impaired cytotoxic function,
consistent with exhaustion after the early acute phase of
infection. LCMV-infected TTR-NP mice also manifested high
serum levels of the immunosuppressive cytokine IL-10
produced by a high number of CD4þCD25þfoxp3þHeliosþ
Tregs. The defect in NP-speciﬁc T-cell function was not due
to liver-intrinsic mechanisms because NP-speciﬁc T-cells
adoptively transferred into RAG-deﬁcient TTR-NP that do
not develop Tregs exhibited enhanced, not impaired, pro-
liferation and cytokine function. Similarly, depletion of
CD25þ cells using an anti-CD25 antibody led to decreased
numbers of CD8þPD-1þ cells, restoration of effector func-
tion, and a decrease of serum IL-10 and viral clearance.
Critically, heterozygote TTR-NP/wild-type mice undersimilar conditions exhibited attenuated generation of
TREGs and relatively normal NP-speciﬁc effector T-cell
function, suggesting that antigen burden is the key factor
driving Treg induction and subsequent suppression. Thus,
the model indicates that high-level expression of a viral
antigen in hepatocytes leads to the development of Tregs
that interfere with CD4þ and CD8þ effector T-cell re-
sponses, impairing early viral clearance and promoting
chronic infection.
The authors should be lauded for well-constructed ex-
periments that address a critical gap in our understanding
of the immunopathogenesis of chronic hepatic infections.
The two most original features of this model are that 1)
chronic liver damage is induced by polyclonal T-cells in the
context of an active viral infection, and 2) antigen expres-
sion can be partially modulated. How authentically does this
mouse model recapitulate human acute to chronic viral
hepatitis? Unlike chronic viral hepatitis, viral antigen is
expressed constitutively as a self-antigen in all hepatocytes.
Thus, generation of peripheral tolerance to viral antigens
could predate viral infection. It is unknown to what extent
viral antigen expression in this model mimics antigen
expression in human hepatocytes infected with HCV or HBV.
Further, the critical link between early innate and adaptive
immunity cannot be probed because LCMV, unlike HCV,
does not directly interfere with RIG-I-like receptor signaling
and early type I interferon induction.12
Despite these limitations, the work of Lapierre et al
strongly supports a critical role for CD4þfoxp3þIL-10þ
Tregs in inducing antigen-speciﬁc T-cell tolerance and the
establishment of chronic hepatic viral infection. These data,
combined with a myriad of translational human ex vivo and
in vitro studies, suggest that therapeutic manipulation of
Tregs either via depletion or inactivation may be worth
investigating as treatment for chronic hepatitis B virus and
drug-resistant HCV infections.
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